Concord Wealth Partners Aptinyx Inc. Transaction History

Concord Wealth Partners

  • $591 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 27, 2023
BUY
$0.23 - $0.34 $2,300 - $3,400
10,000 New
10,000 $2,000
Q2 2022

Aug 04, 2022
SELL
$0.38 - $2.58 $1,520 - $10,320
-4,000 Closed
0 $0
Q4 2021

Jan 21, 2022
BUY
$2.11 - $3.0 $8,440 - $12,000
4,000 New
4,000 $11,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email